Northern Trust Corp increased its position in shares of GSK plc (NYSE:GSK - Free Report) by 16.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,060,255 shares of the pharmaceutical company's stock after acquiring an additional 287,211 shares during the period. Northern Trust Corp owned about 0.10% of GSK worth $69,678,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also made changes to their positions in the company. Dodge & Cox boosted its position in GSK by 0.5% in the fourth quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company's stock valued at $2,314,672,000 after buying an additional 353,749 shares in the last quarter. FMR LLC boosted its position in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after buying an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA boosted its position in GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after buying an additional 10,407,905 shares in the last quarter. Fisher Asset Management LLC boosted its position in GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock valued at $637,061,000 after buying an additional 259,867 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in GSK by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock valued at $255,914,000 after buying an additional 35,134 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.
Analyst Ratings Changes
A number of analysts have weighed in on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target for the company. Finally, Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $40.58.
View Our Latest Research Report on GSK
GSK Stock Down 0.7%
GSK traded down $0.24 during midday trading on Friday, hitting $36.63. The company had a trading volume of 3,511,468 shares, compared to its average volume of 4,786,523. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $75.58 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 1.12 and a beta of 0.51. The stock's 50 day moving average price is $37.65 and its 200 day moving average price is $35.97.
GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business's revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 earnings per share. On average, research analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.
GSK Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.60%. GSK's payout ratio is presently 86.60%.
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
